中药糖肾方治疗早期2型糖尿病肾病:随机对照试验研究方案
本研究为13中心、随机、双盲、安慰剂对照试验,计划纳入632例早期2型糖尿病肾病患者,按1:1随机分为糖肾方联合氯沙坦组与安慰剂联合氯沙坦组,疗程24周。主要结局为尿微量白蛋白-肌酐比值从基线至第24周的变化,次要结局包括临床蛋白尿期进展率、尿微量白蛋白转阴率等。研究假设糖肾方可使早期糖尿病肾病患者获益。
要点
- 糖肾方联合氯沙坦与安慰剂联合氯沙坦对照,评估早期糖尿病肾病疗效。
- 主要结局为24周尿微量白蛋白-肌酐比值较基线变化。
- 试验为13中心、随机双盲安慰剂对照设计,计划样本632例。
核心结论
- 研究假设早期2型糖尿病肾病患者可从糖肾方治疗中获益。
- 若试验成功,将为临床医生提供循证推荐依据。
研究设计与样本
- 13中心、随机、双盲、安慰剂对照试验,计划纳入632例受试者。
- 受试者按1:1随机分为糖肾方联合氯沙坦组与安慰剂联合氯沙坦组,疗程24周。
- 试验注册号NCT03009864,2017年1月注册。
关键数值与推荐
- 主要结局为尿微量白蛋白-肌酐比值从基线至第24周的变化。
- 次要结局包括临床蛋白尿期进展率、尿微量白蛋白转阴率、尿微量白蛋白正常率、基线肌酐值倍增率及肾小球滤过率组间差异。
- 同时评估用药安全性。
临床怎么用
- 若研究达到预期,可为临床医生在早期糖尿病肾病中应用糖肾方提供循证建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetic kidney disease (DKD) is the main cause of end-stage kidney disease and has become a heavy economic and social burden due to its high prevalence and morbidity. The most effective strategy is that patients with DKD should be diagnosed and treated early. Preliminary studies showed that the Chinese herbal Tangshen Formula (TSF) may delay the progression of DKD, reducing microalbuminuria and macroalbuminuria and improving renal function. We designed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of TSF in patients with DKD. METHODS/DESIGN: This trial is a 13-center, randomized, double-blind, placebo-controlled study. A total of 632 participants will be randomized in a 1:1 ratio to an experiment group (TSF plus losartan) and a control group (placebo plus losartan). The trial cycle will last 24 weeks. The primary outcome will be the change in the urine microalbumin-creatinine ratio from baseline to week 24. The secondary outcome will be the change in the rate of progression to the clinical proteinuria period after intervention, the rate of urine microalbumin negative conversion, the rate of normal urinary microalbumin, the doubling rate of the baseline creatinine value and the glomerular filtration rate between the two groups. Safety in medication will also be evaluated. DISCUSSION: We hypothesize that patients with type 2 diabetes in the early stage of DKD will benefit from TSF. If successful, this study will provide evidence-based recommendations for clinicians. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03009864. Registered January 2017.
引用
- Jin D, Huang WJ, Meng X, et al. Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial. Trials. 2019. PMID: 31864393. doi:10.1186/s13063-019-3821-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。